We recently contacted all stakeholders for the appraisal of cannabidiol for treating seizures caused by tuberous sclerosis complex regarding a delay to this topic for operational reasons.
Cannabidiol for treating seizures caused by tuberous sclerosis complex has now been rescheduled into the work programme. The appraisal is due to start mid-January 2022 and will be discussed at committee in mid-September 2022.
The new timelines are subject to the work programme capacity and we will continue to review our plans in collaboration with the company and update our stakeholders accordingly.